Clinical impact of confinement due to the COVID-19 pandemic on patients with fibromyalgia: a cohort study

J. Rivera¹, I. Castrejón¹, L. Vallejo-Slocker², M. Offenbächer³, J. Molina-Collada¹, L. Trives¹, K. López¹, L. Caballero¹, J.K. Hirsch⁴, L. Toussaint⁵, J.C. Nieto¹, J.M. Alvaro-Gracia¹, M.A. Vallejo²

¹Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid; ²Department of Clinical Psychology, National Distance Education University (UNED), Madrid, Spain; ³Gasteiner Heilstollen Hospital, Bad Gastein-Böckstein, Austria; ⁴Department of Psychology, East Tennessee State University, Johnson City, USA; ⁵Department of Psychology, Luther College, Decorah, Iowa, USA.

ABSTRACT

Objective. To our knowledge, the impact of the COVID-19 pandemic on fibromyalgia (FM) patients has not been studied before. FM patients often experience clinical impairment with stress. The aim of this study was to determine whether severity of FM increases because of confinement by the COVID-19 pandemic.

Methods. This prospective study includes patients from the Combined Index of Severity of Fibromyalgia (ICAF) cohort who met the 2010 ACR FM criteria. In this cohort, all patients have a periodical evaluation of their quality of life through two questionnaires, the ICAF, which assesses the ability to perform daily living activities, anxiety and depression, and through the Patient Global Impression of Change (PGIC), which assesses overall change after a therapeutical intervention. Pre- and post-confinement measurements were analysed. Inferential statistical analysis and ANOVA for repeated measurements were used.

Results. A total of 93 patients received a phone consultation, (95.5% females), mean (SD) age of 48.23 (8.38) years. Four patients were excluded as presenting COVID-19 and 51 (57%) completed the post-confinement ICAF. Following confinement, 25 (49%) patients got worse (group-worse) and 26 (51%) patients experienced no change or improved (group-stable). Comparisons between pre- and post-confinement ICAF did not show significant differences in both groups. Passive coping was significantly different in group-worse in pre-confinement evaluation. In the 80% of patients with passive coping predominance there were no changes in coping strategy.

Conclusion. No clinical impairment due to COVID-19 confinement occurred. The perceived worsening among FM patients relies primarily on how patients cope with their disease, without a real impact on clinical manifestations.

Introduction

In response to the coronavirus pandemic (COVID-19), many European countries have implemented non-pharmacological interventions, such as national lockdowns. In Spain, this measure was especially hard, lasting 3 months during which only health and essential public service workers were allowed to move to the workplace. The psychological impact among the general population caused by quarantine imposed by other infectious diseases has been the subject of a recent review (1). Most studies show negative psychological effects with symptoms related to post-traumatic stress, confusion and anger. In patients with chronic diseases this psychological impact may be even higher as these patients suffer added stressors related to their own disease (2). Psychosocial factors may play a role in the development of fibromyalgia (FM) (3) and the patients with this disease often have an increase in clinical manifestations in stressful situations. These are primarily caused by physical or emotional trauma requiring good adaptation mechanisms (4). In this sense, a stressful situation such as confinement may have increased the severity of the clinical manifestations of FM.

The objective of this work is to examine the impact of confinement by the COVID-19 pandemic on patients with FM.

Methods

Patients

In 2010 we started a hospital-based cohort of patients with FM -the Combined
Index of Severity in Fibromyalgia (ICAF) cohort- to characterise clinical course and use of treatments through the ICAF questionnaire (5). Inclusion criteria are: being older than 18 years and fulfilling the 2010 American College of Rheumatology (ACR) FM criteria (6). At baseline main demographic data and information about treatment is collected, and the patients complete the ICAF questionnaire (5). Treatment is prescribed by the treating rheumatologist and a follow-up visit is recorded at 3 months in which patients complete a new ICAF questionnaire with information about their treatment. During the follow-up visit, patients also complete a Patient Global Impression of Change (PGIC) (7) questionnaire to evaluate the effect of initial treatment on their overall health status. Subsequently, new evaluations are made at 1, 3 and 5 years of follow-up. Currently, 1100 patients are included in this cohort with a different number of visits.

**Questionnaires**

ICAF (5, 8) is a specific quality-of-life questionnaire for FM patients, offering a total score of the severity of the disease along with four other factors. The physical factor measures the functional ability from the point of view of physical capacity to perform daily activities; the emotional factor measures the severity of clinical manifestations such as anxiety and depression; and two factors of active and passive coping measure the attitude of the patient in coping with their disease. All scores are expressed on a T-scale with an average of 50 and a standard deviation of 10. A high score indicates greater severity, with the exception of the active coping factor that indicates a better coping. The importance of each factor over the other can also be assessed.

This questionnaire has been previously validated in our population (5). The PGIC (7) is a specific questionnaire to evaluate overall improvement after an intervention. It includes a Likert scale from 1 to 7 (1 = much better, 2 = better, 3 = a little better, 4 = equal, 5 = a little worse, 6 = worse or 7 = much worse) to assess how the patient is feeling after an intervention. This questionnaire has been validated in patients with FM (9) to assess the perception of overall improvement experienced after a therapeutic intervention and is widely used in studies on chronic pain and FM.

**Study design**

This is a longitudinal study with pre- and post-confinement measurements of ICAF and PGIC outcome variables. The confinement period in Spain was from March 14th to June 24th, 2020. During this confinement period, all consultations for patients with FM were conducted by telephone at our Unit. During July 2020 all FM patients included in this cohort -attended by phone consultation on a scheduled basis- were asked to assess their status of the severity of symptoms compared to the pre-confinement situation through the PGIC questionnaire (PGIC-post). At the end of the phone consultation, they were mailed an ICAF questionnaire and requested to mail it back (ICAF-post) once completed. All patients consented verbally to the phone consultation. The last available pre-confinement ICAF (ICAF-pre) was used for comparison with the ICAF-post. For comparison purposes, the PGIC after treatment initiation when entering the cohort (PGIC-pre) was used.

**Statistical analysis**

For statistical analysis, the t-test was used to compare quantitative variables and the chi-square test for qualitative variables. To analyse the evolution between the ICAF-pre and the ICAF-post, an ANOVA for repeated measurements was used.

**Results**

During the study period, 93 FM patients from the cohort treated by phone consultation were identified (Fig. 1). Four patients who had had Covid-19 were excluded, leaving a total of 89 patients for analysis, (95.5% were females), mean (SD) age of 48.2 (8.4) years.

Only 51 (57.3%) patients mailed back the ICAF-post questionnaire. No significant differences in age, ICAF-pre, PGIC-pre or PGIC-post were found between patients who mailed the ICAF-post and those who did not.

From the 51 patients with a follow-up evaluation by ICAF-post, the PGIC-post showed improvement in 11 patients (22%), 25 (49%) were worse, and 15 (29%) experienced no change in their clinical status after confinement. For subsequent comparisons two groups were formed: group-worse, including 25 (49%) patients who had worsened, and group-stable, with 26 (51%) patients who experienced improvement or no change.

There were not statistically significant differences in age and gender between groups.

In the ICAF-pre, although there was a tendency to a higher severity in patients in the group-worse, this difference did not reach statistically significant differences in each factor except for the passive coping, which was significantly worse in patients in this group (p<0.022) (Table I). The ICAF-post analysis showed greater severity in patients in group-worse, with statistically significant differences in total score.
Confinement impact due to COVID-19 in fibromyalgia / J. Rivera et al.

**Table I.** Comparison of pre- and post-confinement ICAF, total score and individual factors.

<table>
<thead>
<tr>
<th>Factors</th>
<th>Group</th>
<th>n</th>
<th>ICAC-pre mean</th>
<th>SD</th>
<th>p between groups</th>
<th>ICAF-post mean</th>
<th>SD</th>
<th>p between groups</th>
<th>Comparison between ICAC-pre and ICAC-post</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical</td>
<td>worse</td>
<td>25</td>
<td>53.75</td>
<td>10.96</td>
<td>ns</td>
<td>54.80</td>
<td>9.29</td>
<td>0.035</td>
<td>0.291  1.24  0.595 (.012)</td>
</tr>
<tr>
<td></td>
<td>stable</td>
<td>26</td>
<td>50.01</td>
<td>13.04</td>
<td>ns</td>
<td>47.77</td>
<td>13.38</td>
<td>0.035</td>
<td>1.127  1.25  0.298 (.043)</td>
</tr>
<tr>
<td>Emotional</td>
<td>worse</td>
<td>25</td>
<td>54.15</td>
<td>11.44</td>
<td>ns</td>
<td>56.77</td>
<td>9.10</td>
<td>0.015</td>
<td>1.796  1.24  0.193 (.070)</td>
</tr>
<tr>
<td></td>
<td>stable</td>
<td>26</td>
<td>49.99</td>
<td>11.26</td>
<td>ns</td>
<td>49.16</td>
<td>12.23</td>
<td>0.015</td>
<td>0.113  1.25  0.740 (.044)</td>
</tr>
<tr>
<td>Active coping</td>
<td>worse</td>
<td>25</td>
<td>52.55</td>
<td>10.93</td>
<td>ns</td>
<td>53.58</td>
<td>9.10</td>
<td>ns</td>
<td>0.277  1.24  0.604 (.011)</td>
</tr>
<tr>
<td></td>
<td>stable</td>
<td>26</td>
<td>50.81</td>
<td>12.85</td>
<td>ns</td>
<td>48.28</td>
<td>12.78</td>
<td>ns</td>
<td>1.696  1.25  0.205 (.064)</td>
</tr>
<tr>
<td>Passive coping</td>
<td>worse</td>
<td>25</td>
<td>55.71</td>
<td>7.97</td>
<td>0.022</td>
<td>58.10</td>
<td>9.58</td>
<td>ns</td>
<td>1.738  1.24  0.200 (.068)</td>
</tr>
<tr>
<td></td>
<td>stable</td>
<td>26</td>
<td>50.22</td>
<td>8.51</td>
<td>0.022</td>
<td>51.56</td>
<td>10.23</td>
<td>0.023</td>
<td>0.407  1.25  0.529 (.016)</td>
</tr>
</tbody>
</table>

ICAF: Combined Index of Severity of Fibromyalgia; n: number of patients; SD: standard deviation; F: value; df: degree of freedom; es: effect size.

(\(p<0.035\)), physical factor (\(p<0.015\)) and passive coping (\(p<0.023\), but not in emotional factor or active coping (Table I).

When analysing the evolution of patient severity comparing ICAF-pre with ICAF-post, no significant differences were found in either group suggesting that there had been no clinical impairment in patients with respect to their previous situation (Table I).

The predominance of the factors in the ICAF-pre (passive vs. active and emotional vs. physical) in both groups is shown in Table II.

The predominance of passive coping was higher in group-worse, but it did not reach statistical significance. The predominance of emotional factors was also similar in both groups. Of the 15 patients in group-worse with the predominance of passive coping in the ICAF-pre, 12 (80%) of them continued to have a predominance of passive coping when they performed the ICAF-post. In the PGIC-pre, 17 (33%) of the total number of patients responded they were worse after the initial treatment of the first visit. Of these, 11 (65%) patients responded again that they were worse in the PGIC-post.

**Discussion**

Patients with FM experienced a worsening in their health status after confinement during the COVID-19 pandemic in our cohort. Since we initially excluded all patients who had had clinical manifestations compatible with COVID-19, the worsening of their health status may be attributed directly to the stressors surrounding the confinement.

To our knowledge, this is the first study specifically designed to analyse the impact of COVID-19 pandemic quarantine on the health status in patients with FM. In a recent study (1) which evaluated the impact of confinement on patients with various chronic diseases it was found that 48% of them had worsened their perceived health status. Our findings show that the impact of confinement on FM patients is probably similar to that of any other chronic disease.

In patients who reported a worsening of their health status after confinement, the total score of ICAF, as well as the physical factor (which measures variables such as pain, sleep quality or daily life activities), and the emotional factor (which mainly measures anxiety and depression), showed no significant differences with the situation before confinement, suggesting that there had not been a clear worsening of the main clinical manifestations of FM. Only passive coping (which measures the patient’s attitude towards their disease along with the coping strategies they are able to develop) was significantly worse both in the previous situation and after confinement. In this sense, 80% of the patients who were worse had already had a predominant passive coping before confinement.

It is noteworthy that passive coping has little influence on the total score of the ICAF questionnaire, since it explains only 6% of the variance in the construction of the questionnaire, with the physical and emotional factors being the most relevant (8). This suggests that the perceived worsening among FM patients in our study as a result of COVID-19 pandemic confinement depends primarily on how patients cope with their disease, without a real impairment of the clinical manifestations measured by physical or emotional factors. In the general population, some variables such as female sex, the
Confinement impact due to COVID-19 in fibromyalgia / J. Rivera et al.

The prevalence of FM is around 2.5% of the general population (12), so an increase in the clinical manifestations of these patients or a rise in the prevalence of this disease may have outstanding consequences in the healthcare system of any country.

The main strength of our study is that we have a measure of quality of life in FM patients prior to the confinement by the COVID-19 pandemic that has allowed us to compare with the situation after the confinement. Several limitations are present in our study. First, the low response rate of 57%, which may underestimate the impact of confinement on FM. Second, we did not collect other relevant variables such as level of education, the number of people at home or lonely, which have been associated with a worse situation after confinement in the general population. Third, our results need to be evaluated in other cohorts of FM patients.

Conclusions

In this study, we show that confinement during the COVID-19 pandemic has a negative impact on patients with FM. This depends primarily on how patients cope with their disease, without a real impairment of clinical manifestations.

References


absence of higher education, the number of people at home or lonely, are associated with a worse situation after confinement (1). On the other hand, in patients with chronic diseases the variables associated with worsening are also related to aspects of daily life and do not seem to be related to the clinical manifestations of the disease, except for the duration of the disease itself (2). In other situations of collective stress in society, such as the World Trade Center terrorist attack in 2001, there was also no significant worsening of symptoms in FM patients (10). In this study, previous depressive pathology was also unable to predict worsening of symptoms, as well as previous FM symptoms such as pain or other psychiatric symptoms (10).

In addition to the psychological impact of confinement, as we have studied here, there are other possibilities for the COVID-19 pandemic to produce an impairment in the health situation of FM patients. Currently it is not known whether the infection with coronaviruses SARS-cov2 may produce long-term chronic clinical manifestations such as fatigue, myalgias, arthralgias or cognitive alterations compatible with chronic fatigue syndrome or FM, as it occurs in other infectious viral diseases (11).

If the current COVID-19 pandemic lasts much longer, as it seems to be happening, an increase in new FM cases may occur, especially among the most predisposed patients or those with other chronic inflammatory diseases that add another major stressor for these patients.